Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon Pharmaceuticals has obtained positive results from its initial Phase I clinical trial of LX2931, an orally-delivered, small molecule drug candidate for the treatment of rheumatoid arthritis and other autoimmune conditions.
Subscribe to our email newsletter
LX2931 is one of four programs in human clinical trials as part of Lexicon’s 10TO10 program. Initial results from this single ascending-dose trial in healthy volunteers demonstrated a potent, dose-dependent reduction in circulating lymphocytes, suggesting that the target of LX2931 may represent a new mechanism for regulating the immune response.
Philip Brown, senior vice president of clinical development at Lexicon, said: “We are encouraged not only by the rapid onset of action, but also by the timely recovery of lymphocyte counts as the drug candidate is cleared from the system. Based on these results, we are actively pursuing a multidose trial with LX2931.”